GlassScriptPhysician profile
Taher Husainy
NPI 1083693279
$3,847.83
in general payments reported to CMS, 2019-2025
34 companies · $280 in 2025
The $280 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $422 · 2020: $233 · 2021: $636 · 2022: $540 · 2023: $513 · 2024: $1,224 · 2025: $280.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,017.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,017.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $481.07 | 2022-2025 | Mavenclad, Mavenclad |
| Abbvie INC. | $403.24 | 2021-2024 | |
| Biogen, INC. | $375.48 | 2020-2024 | Vumerity, Tysabri, Avonex |
| Ucb, INC. | $276.85 | 2019-2021 | |
| Lilly USA, LLC | $221.54 | 2020-2024 | Amyvid, Kisunla |
| Teva Pharmaceuticals USA, INC. | $184.27 | 2019-2024 | Austedo Xr |
| Mdd US Operations, LLC | $172.21 | 2019-2024 | Apokyn |
| Tanabe Pharma America, INC. | $146.30 | 2020-2022 | |
| Abbott Laboratories | $145.88 | 2024 | Aveir |
| Alexion Pharmaceuticals, INC. | $139.87 | 2022-2025 | Ultomiris, Soliris |
| Pfizer INC. | $130.90 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $126.59 | 2019-2024 | |
| Argenx US, INC. | $125.83 | 2023-2025 | Vyvgart, Vyvgart Hytrulo |
| Celgene Corporation | $113.43 | 2024-2025 | Zeposia |
| Sunovion Pharmaceuticals INC. | $89.29 | 2021-2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $80.75 | 2023-2024 | Hyqvia, Gammagard |
| Eisai INC. | $79.33 | 2023-2024 | |
| Biohaven Pharmaceuticals, INC. | $69.02 | 2021 | |
| Genzyme Corporation | $62.44 | 2019-2022 | |
| Alnylam Pharmaceuticals INC. | $55.26 | 2022-2024 | Onpattro |
| Acadia Pharmaceuticals INC | $45.33 | 2024-2025 | Nuplazid |
| Impel Pharmaceuticals INC. | $37.95 | 2022-2023 | Trudhesa |
| Janssen Pharmaceuticals, INC | $37.36 | 2021 | |
| Amneal Pharmaceuticals LLC | $35.43 | 2021-2024 | Rytary |
| Csl Behring | $31.88 | 2024 | Hizentra |
| Lundbeck LLC | $29.79 | 2024 | Rexulti |
| Mallinckrodt Enterprises LLC | $24.84 | 2019 | |
| Vanda Pharmaceuticals INC. | $21.64 | 2024 | Ponvory |
| Kyowa Kirin, INC. | $21.22 | 2021 | |
| Upsher-Smith Laboratories LLC | $21.14 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.50 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $18.47 | 2022 | |
| Corium, LLC | $13.01 | 2023 | Adlarity |
| Kvk-Tech, INC. | $11.72 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Taher Husainy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.